Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRANFORD, N.J., June 8, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that the next planned interim analysis in its Phase 3 trial of Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related blood stream infections (CRBSIs/CLABSIs) has been scheduled for the end of June 2021.

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

CRANFORD, N.J., June 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.

Citius Pharmaceuticals to be Added to Russell 2000® Index

Specialty pharmaceutical company Citius Pharmaceuticals is dedicated to developing and commercializing therapeutic products for growing markets. Citius' President and CEO Myron Holubiak spoke about the company's four pipeline programs – Milo-Lok, Halo-Lido, Mino-Wrap and iMSC – at the Benzinga Global Small Cap Business Conference on May 13, 2021.

Citius Pharmaceuticals Introduces Milo-Lok

CRANFORD, N.J., May 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it has received the Best Poster Award at the prestigious International Society for Cell and Gene Therapy (ISCT) 2021 Annual Meeting.

Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting

Allied Esports Entertainment Inc

Professional Diversity Network

3 penny stocks that are wildly popular on Reddit and WallStreetBets The post Penny Stocks to Buy? 3 That WallStreetBets Won't Stop Talking About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy? 3 That WallStreetBets Won't Stop Talking About

CRANFORD, N.J., May 18, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it will present a poster at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting, to be held virtually May 26-28, 2021.

Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy

CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.

Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

Applied Genetic Technologies

Atossa Genetics

Clover Health Investments

Senseonics Holdings

InvestorPlace is closing out a busy week of trading with a look at the Reddit penny stocks seeing the most chatter on Friday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Friday appeared first on InvestorPlace.

5 Reddit Penny Stocks Seeing the Most Chatter Friday

Myron Holubiak, president and CEO of Citius Pharmaceuticals Inc (NASDAQ: CTXR), appeared Thursday at Benzinga's Global Small Cap Conference for an exclusive interview. The name Citius Pharmaceuticals comes from the Olympic motto "Citius, Altius, Fortius," which is Latin for "Faster, Higher, Stronger," Holubiak told Benzinga.

EXCLUSIVE: Citius Pharmaceuticals CEO Myron Holubiak Talks Company Advantages

CRANFORD, N.J., May 13, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today reported financial results for the second fiscal quarter of 2021 and provided a general business update.

Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update

CRANFORD, N.J., May 11, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium.

Citius Pharmaceuticals to Participate in Fireside Chat at the Gabelli Funds Virtual Microcap Symposium on Tuesday, May 18

AMC Entertainment

Bionano Genomics

Nokia

Tenet Healthcare

We're taking another dive into the world of penny stocks on Tuesday with a look at Reddit's most-talked-about for the day. The post 5 Reddit Penny Stocks Seeing the Most Chatter Tuesday appeared first on InvestorPlace.

5 Reddit Penny Stocks Seeing the Most Chatter Tuesday

Oragenics

Safe Bulkers

Best penny stocks to watch in 2021? Here are 3 for your long term watchlist The post Trending Penny Stocks To Watch in 2021?

Trending Penny Stocks To Watch in 2021? Take a Look At These

VistaGen Therapeutics

Penny stocks present opportunities to buy the dip often; is that the case with these biotech stocks? The post Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?

Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?

CRANFORD, N.J., April 29, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third Mino-Lok® Phase 3 trial-related webinar.

Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar

CRANFORD, N.J., April 22, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Citius President and CEO, Myron Holubiak, was featured in an interview with Benzinga discussing the Company's product pipeline, the impact of Covid-19, and upcoming milestones.

Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview

180 Life Sciences 

Jaguar Health

Ocugen, Inc.

Savara

Timber Pharmaceuticals

Zosano Pharma

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

7 Reddit Penny Stocks to Buy for a Biotech Boom

American Resources Corp

BlackBerry

Cinedigm

Cronos Group

Riot Blockchain

Yes, these Reddit penny stocks are all reasonably risky plays. But there is growth potential in each of these companies.

Reddit Penny Stocks That Actually Look Pretty Reasonable

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Executive Chairman Leonard Mazur told Benzinga CEO Jason Raznick Thursday that he's invested $26.5 million of his own money in the specialty pharmaceutical company.  Citius is comprised of "all-in entrepreneurs," Mazur said on Benzinga's "Power Hour" YouTube show.

Exclusive: Citius Pharmaceuticals Exec Chairman On Product Pipeline, Potential $1B TAM

It's a great time to hold CTXR stock as the company's CEO shares his vision of significant corporate developments and clinical progress. The post Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals appeared first on InvestorPlace.

Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals

Aytu BioScience

Denison Mines

Hall of Fame Resort & Entertainment

Ideanomics Inc

Marker Therapeutics Inc

Neos Therapeutics

Zomedica

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

10 Reddit Penny Stocks Seeing the Most Chatter Today

Marathon Digital Holdings

SNDL Inc.

TherapeuticsMD

Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

7 Reddit Penny Stocks Seeing the Most Chatter Today

CRANFORD, N.J., March 4, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will present at the H.C. Wainwright Global Life...

Citius Pharmaceuticals to Feature Product Candidates Including Stem-Cell Therapy for COVID-19-Related Acute Respiratory Conditions at H.C. Wainwright Global Life Sciences Conference March 9-10

The stock price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) is trading at over 10% pre-market. This is why it happened.

CTXR Stock Price Increases Over 10% Pre-Market: Why It Happened

CRANFORD, N.J., Feb. 19, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed its previously announced sale...

Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

News for Citius Pharmaceuticals Stock (CTXR)